Kymera Therapeutics, Inc. (KYMR) Financials

KYMR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.7 billion 129.4 million
Dec. 31, 2025 1.7 billion 163.1 million
Sept. 30, 2025 1.1 billion 155.8 million
June 30, 2025 1.1 billion 159.6 million

KYMR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -89.3 million 16.0 million
Dec. 31, 2025 -66.9 million 14.5 million
Sept. 30, 2025 -27.3 million 15.8 million
June 30, 2025 -60.6 million 15.4 million

KYMR Net Income

No data available :(

KYMR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 650.9 million - 80.5 million
Dec. 31, 2025 848.3 million - 68.5 million
Sept. 30, 2025 505.7 million - 70.3 million
June 30, 2025 665.4 million - 85.7 million

KYMR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 97.5 million
Dec. 31, 2025 84.4 million
Sept. 30, 2025 87.3 million
June 30, 2025 80.4 million

KYMR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 434000 98.2 million 20.4 million -
Dec. 31, 2025 106000 83.9 million 16.9 million -
Sept. 30, 2025 181000 74.1 million 17.3 million -
June 30, 2025 695000 78.4 million 17.6 million -

KYMR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 34.4 million 2.0 million
Dec. 31, 2025 2.9 million -76.2 million
Sept. 30, 2025 2.8 million 74.1 million
June 30, 2025 11.5 million 2.1 million

KYMR

Price: $110.57

52 week price:
36.65
130.05

Earnings Per Share: -3.58 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 492600

Market Capitalization: 9.8 billion

Links: